EXAMINE

The EXAMINE CVOT assessed the cardiovascular safety of alogliptin in patients with type 2 diabetes and acute coronary syndrome. This module details the study outcomes.

EXAMINE

EXAMINE
Login or create an account to see restricted content
EXAMINE: trial design
Login or create an account to see restricted content
EXAMINE: baseline characteristics
Login or create an account to see restricted content
EXAMINE: CV disease at baseline
Login or create an account to see restricted content
EXAMINE: renal function at baseline
Login or create an account to see restricted content
EXAMINE: glucose-lowering medication and CV medication at baseline
Login or create an account to see restricted content
EXAMINE: 3P-MACE primary outcome
Login or create an account to see restricted content
EXAMINE: components of 3P-MACE and all‑cause mortality
Login or create an account to see restricted content
EXAMINE: hospitalisation for heart failure
Login or create an account to see restricted content
EXAMINE: initiation of dialysis and changes in eGFR
Login or create an account to see restricted content
EXAMINE: safety overview
Login or create an account to see restricted content
EXAMINE: summary

EXAMINE

EXAMINE

EXAMINE: trial design

EXAMINE: baseline characteristics

EXAMINE: CV disease at baseline

EXAMINE: renal function at baseline

EXAMINE: glucose-lowering medication and CV medication at baseline

EXAMINE: 3P-MACE primary outcome

EXAMINE: components of 3P-MACE and all‑cause mortality

EXAMINE: hospitalisation for heart failure

EXAMINE: initiation of dialysis and changes in eGFR

EXAMINE: safety overview

EXAMINE: summary